Ozurdex intravitreal injection is performed via a patented injection device. However, there is a common misconception among ophthalmologists regarding the relation between the speed of applicator button depression and the speed of pellet injection.
INTRODUCTION
Dexamethasone intravitreal implant (Ozurdex; Allergan, Irvine, CA) is composed of a biodegradable polymer that slowly releases dexamethasone into the vitreous over a number of months. This medication is used to treat macular edema in diseases such as diabetic retinopathy, retinal vein occlusion, and uveitis. Nevertheless, owing to the nature of injecting a physical implant pellet, there is a tangible risk of vitreous hemorrhage and/or retinal damage. [1] [2] [3] The Ozurdex applicator works via an accordion type mechanism (Figure 1 ) that imposes a direct correlation between speed of depression of the actuator and the speed of implant release. There are currently no guidelines on the recommended speed of Ozurdex intravitreal insertion.
TECHNIQUE
The goal of the study was to measure the force of Ozurdex pellet impact as well as pellet velocity in relation to the speed of pressing the insertion button. A test chamber was constructed and filled with water in order to simulate the typical resistance of a vitrectomized eye. A hole was made on the side of the test chamber to allow for insertion of the dexamethasone injector, a grid of 0.2-inch squares was placed behind the test chamber to measure the distance travelled by the pellet, and a high-speed photography camera (240 frames per second) was placed in front of the setup to capture the events The values that were calculated include impact velocity (Vf), which refers to the velocity of the pellet at approximately 16 mm from the tip of the needle to represent the hypothetical location of the retina. Velocity was calculated by measuring the change of pellet position on the square grid relative to the elapsed time recorded by the camera. The force at Vf was calculated by multiplying the average mass of the pellets (1.179 mg) by acceleration at the impact point. Figures 3A and 3B represent the trajectory of the pellet insertion using fast and slow injection techniques, respectively. The results of our study demonstrate that the mean impact velocities for fast and slow injection methods are 273.3 cm/sec ± 20.8 cm/sec and 21.7 cm/sec ± 3.6 cm/sec 
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(P < .0001), respectively. Likewise, the mean pellet forces at impact velocity for fast and slow injection methods are 0.74 mN ± 0.08 mN and 0.04 mN ± 0.027 mN (P < .0002), respectively.
DISCUSSION
Rapid injection of Ozurdex correlates with high speed of pellet insertion, which will likely increase the risk of retinal tear and vitreous hemorrhage. The results of our study demonstrate that injection of Ozurdex during a 3-second period significantly reduces the impact velocity and force of pellet insertion. Therefore, we recommend administering Ozurdex injections by rolling the ball of the thumb across and down from the top of the activation button over a period of 3 seconds (Figure 4) . 
